Abbott Laboratories
ABTNYSEHealthcare● Active
$90.50
$-0.57(-0.63%)
Market Cap$157.6B
P/E Ratio—
52W High$139.06
52W Low$81.97
Abbott Laboratories (ABT) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ABT · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B |
| Depreciation & Amort. | $3.12B | $3.22B | $3.24B | $3.27B | $3.54B |
| Stock-Based Comp. | $0.66B | $0.67B | $0.64B | $0.69B | $0.64B |
| Change in Working Capital | ($0.80B) | ($9.22B) | ($2.48B) | ($1.52B) | ($0.77B) |
| Net Cash from Operations | $9.57B | $8.56B | $7.26B | $9.58B | $10.53B |
| Investing Activities | |||||
| Capital Expenditure | ($2.17B) | ($2.21B) | ($2.20B) | ($1.78B) | ($1.89B) |
| Purchases of Investments | ($0.17B) | ($0.17B) | ($0.16B) | ($0.18B) | ($0.17B) |
| Sales of Investments | $0.00B | $0.03B | $0.04B | $0.15B | $0.08B |
| Net Cash from Investing | ($2.42B) | ($2.34B) | ($3.13B) | ($1.74B) | ($2.01B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.89B) | ($1.29B) | ($1.23B) | ($3.79B) | ($2.30B) |
| Dividends Paid | ($4.12B) | ($3.84B) | ($3.56B) | ($3.31B) | ($3.20B) |
| Debt Issued / Repaid | ($1.61B) | ($0.54B) | ($2.48B) | ($0.70B) | ($0.25B) |
| Net Cash from Financing | ($6.31B) | ($5.40B) | ($7.09B) | ($7.64B) | ($5.49B) |
| Free Cash Flow | |||||
| Free Cash Flow | $7.39B | $6.35B | $5.06B | $7.80B | $8.65B |
| FCF Margin %(computed) | 16.68% | 15.14% | 12.61% | 17.88% | 20.08% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Abbott Laboratories data
About Abbott Laboratories (ABT) Cash Flow Statement
Abbott Laboratories generated operating cash flow of $9.57B and free cash flow of $7.39B for 2025 — a FCF margin of 16.68%. Capital expenditure was ($2.17B).
Frequently asked questions
ABT · 4 questionsAbbott Laboratories generated free cash flow of $7.39B for 2025, up 16.4% year-over-year.
ABT free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10